英国骨髓瘤研究联盟风险谱在新药治疗不适合移植多发性骨髓瘤患者中的评估
本研究回顾性分析了日本J-CHARGE-MM数据库中799例2011年1月至2023年1月诊断的不适合移植新诊断多发性骨髓瘤患者,评估MRP的预后价值。结果显示三个MRP风险组的总生存期差异显著(p<0.01),调整治疗时期和一线治疗后MRP仍为独立预后因素。但在达雷妥尤单抗为基础治疗的患者中,MRP风险组间OS无差异。
要点
- MRP可显著区分不适合移植NDMM患者的总生存期(p<0.01)。
- 调整治疗时期和一线治疗后,中危vs低危HR 1.71,高危vs低危HR 2.61,均p<0.01。
- 在达雷妥尤单抗为基础治疗的患者中,MRP风险组间OS无差异。
核心结论
- MRP是接受新药治疗的真实世界不适合移植NDMM患者的稳健预后工具。
- 在达雷妥尤单抗为基础的治疗时代,MRP的预后效用需进一步研究。
研究设计与样本
- 回顾性分析日本J-CHARGE-MM数据库,纳入799例2011年1月至2023年1月诊断的不适合移植新诊断多发性骨髓瘤患者。
主要发现
- 三个MRP风险组的总生存期差异显著(p<0.01)。
- 调整治疗时期和一线治疗后,MRP风险组仍为独立预后因素:中危vs低危HR 1.71(p<0.01),高危vs低危HR 2.61(p<0.01)。
- 亚组分析中,MRP分类可显著预测硼替佐米为基础和来那度胺为基础治疗患者的OS。
- 在达雷妥尤单抗为基础治疗的患者中,MRP风险组间OS无差异。
临床怎么用
- MRP可用于接受硼替佐米或来那度胺为基础方案的不适合移植NDMM患者的预后分层。
- 在达雷妥尤单抗为基础治疗的患者中,MRP的预后价值尚不明确,需谨慎解读。
局限性
- 回顾性研究设计。
- 数据来源于日本J-CHARGE-MM数据库,外推性需验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The heterogeneity of multiple myeloma (MM) significantly impacts treatment outcomes. Myeloma risk profile (MRP), introduced by the UK Myeloma Research Alliance, is a novel prognostic model for patients with transplant-ineligible newly diagnosed MM (TIE-NDMM) utilizing easily available clinical parameters. In this study, we evaluated the prognostic value of MRP in TIE-NDMM patients treated with novel agents. We retrospectively analysed the data of 799 evaluable MM patients diagnosed between January 2011 and January 2023, extracted from the Japan Clinical Hematology Research Group-EAST (J-CHARGE)-MM database. Overall survival (OS) differed significantly across the three MRP risk groups (p < 0.01). The MRP risk groups remained independently prognostic when adjusted for treatment period and first-line therapy (medium vs. low: hazard ratio [HR], 1.71; p < 0.01; high vs. low: HR, 2.61; p < 0.01). In subgroup analyses, the MRP classification significantly predicted OS in patients treated with bortezomib-based and lenalidomide-based regimens. However, there was no difference in OS between the MRP risk groups in patients treated with daratumumab-based regimens. MRP is a robust prognostic tool for real-world TIE-NDMM patients treated with novel agents. Further studies are warranted to clarify its prognostic utility in the era of front-line anti-CD38 monoclonal antibody-based therapies.
引用
- Nakayama H, Nakazato T, Takahata A, et al. Evaluation of the UK Myeloma Research Alliance risk profile in transplant-ineligible multiple myeloma patients treated with novel agents. Br J Haematol. 2026. PMID: 42692463. doi:10.1111/bjh.70810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。